I don't understand this. If it's the same drug for both trials, why would you partner for one and not the other. I doubt manufacture or end sales would be allocated to one condition and not the other.
Ann: Quarterly Appendix 4C and Activities Report, page-213
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.8¢ |
Change
0.038(8.52%) |
Mkt cap ! $255.8M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 48.0¢ | 44.0¢ | $1.142M | 2.452M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1967 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 62499 | 6 |
View Market Depth
| Last trade - 12.58pm 10/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |